Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

#4319

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Aim(s): To evaluate the effects of the combination of Everolimus and Orlistat on the proliferation, apoptosis, and related signalling pathways in NET cells.

Materials and methods: Human NET cell lines were cultured and treated with varying concentrations of Everolimus and Orlistat, both alone and in combination. Cell viability was assessed using the MTT assay. Apoptosis was evaluated by flow cytometry, and Western blotting was performed to analyse the expression of apoptosis-related proteins (Caspase-3, Cyclin D1, CDK4) and signalling pathways (mTOR, PI3K/Akt). A xenograft model was established by injecting NET cells subcutaneously into immunocompromised mice, which were then treated with either drug alone or in combination. Tumour volume was measured weekly.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,